Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC027 universal CAR-T in relapsed/refractory CD7-positive T-ALL and T-LBL
ISRCTN19144142Phase 2Completed
- Sponsor
- Gracell Biotechnologies
- Start
- Jan 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CD7-CART in t-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) (3 arms), sponsored by Gracell Biotechnologies. Primary endpoints: Dose-limiting toxicity, Adverse events and 1 more. Started Jan 2020; status: completed.
02
Drugs
CD7-CART
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on ISRCTN19144142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN19144142.